CO2017011294A2 - Procedimiento para la preparación de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridina-4-il]fenoxi}etil-l-alanil-l-alaninato-monohidrocloruro - Google Patents

Procedimiento para la preparación de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridina-4-il]fenoxi}etil-l-alanil-l-alaninato-monohidrocloruro

Info

Publication number
CO2017011294A2
CO2017011294A2 CONC2017/0011294A CO2017011294A CO2017011294A2 CO 2017011294 A2 CO2017011294 A2 CO 2017011294A2 CO 2017011294 A CO2017011294 A CO 2017011294A CO 2017011294 A2 CO2017011294 A2 CO 2017011294A2
Authority
CO
Colombia
Prior art keywords
preparation
alaninate
monohydrochloride
sulfanyl
alanyl
Prior art date
Application number
CONC2017/0011294A
Other languages
English (en)
Inventor
Franz-Josef Mais
Werner Heilmann
Britta Olenik
Birgit Keil
Guido Becker
Daniel Meibom
Thomas Kuhlmann
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CO2017011294A2 publication Critical patent/CO2017011294A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente solicitud se refiere a un procedimiento nuevo y mejorado para la preparación del compuesto 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridina-4-il]fenoxi}etil-L-alanil-L-alaninato-monohidrocloruro de la fórmula (I), (I) nuevas fases previas para su preparación y la preparación y uso de la modificación crista-lina I de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)-piridina-4-il]¬fenoxi}etil-L-alanil-L-alaninato-monohidrocloruro de la fórmula (I).
CONC2017/0011294A 2015-05-06 2017-11-02 Procedimiento para la preparación de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridina-4-il]fenoxi}etil-l-alanil-l-alaninato-monohidrocloruro CO2017011294A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15166606 2015-05-06
EP15192030 2015-10-29
PCT/EP2016/059779 WO2016188711A1 (de) 2015-05-06 2016-05-02 Verfahren zur herstellung von 2-{4-[2-({[2-(4-chlorphenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyan-6-(pyrrolidin-1-yl)pyridin-4-yl]phenoxy}ethyl-l-alanyl-l-alaninat-monohydrochlorid

Publications (1)

Publication Number Publication Date
CO2017011294A2 true CO2017011294A2 (es) 2018-01-16

Family

ID=55969107

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0011294A CO2017011294A2 (es) 2015-05-06 2017-11-02 Procedimiento para la preparación de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridina-4-il]fenoxi}etil-l-alanil-l-alaninato-monohidrocloruro

Country Status (32)

Country Link
US (1) US20180155336A1 (es)
EP (1) EP3292133B1 (es)
JP (1) JP2018516882A (es)
KR (1) KR20180002698A (es)
CN (1) CN107531688A (es)
AU (1) AU2016268920A1 (es)
BR (1) BR112017023852A2 (es)
CA (1) CA2984984A1 (es)
CL (1) CL2017002764A1 (es)
CO (1) CO2017011294A2 (es)
CU (1) CU20170136A7 (es)
DK (1) DK3292133T3 (es)
EA (1) EA201792422A1 (es)
EC (1) ECSP17072780A (es)
ES (1) ES2744227T3 (es)
HK (1) HK1246290A1 (es)
HR (1) HRP20191596T1 (es)
HU (1) HUE044787T2 (es)
IL (1) IL255208A0 (es)
LT (1) LT3292133T (es)
MA (1) MA42039A (es)
MX (1) MX2017014134A (es)
PE (1) PE20180204A1 (es)
PH (1) PH12017502010A1 (es)
PL (1) PL3292133T3 (es)
PT (1) PT3292133T (es)
SG (1) SG11201708747PA (es)
SI (1) SI3292133T1 (es)
TN (1) TN2017000466A1 (es)
TW (1) TW201713651A (es)
UY (1) UY36664A (es)
WO (1) WO2016188711A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018108884A1 (de) 2016-12-16 2018-06-21 Bayer Pharma Aktiengesellschaft Pharmazeutische tablettenformulierung
WO2019180072A1 (en) 2018-03-22 2019-09-26 Bayer Pharma Aktiengesellschaft Parenteral pharmaceutical composition comprising neladenoson bialanate
TWI721449B (zh) * 2019-06-11 2021-03-11 行政院原子能委員會核能研究所 2-[[2-[[[3-(4-氯苯基)-8-甲基-8-氮雜雙環[3.2.1]-辛-2-基]-甲基](2-巰基乙基)胺基]乙基]胺基]乙硫醇-[1r(外向-外向)]三鹽酸化物之純化方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension

Also Published As

Publication number Publication date
SG11201708747PA (en) 2017-11-29
HK1246290A1 (zh) 2018-09-07
SI3292133T1 (sl) 2019-08-30
HUE044787T2 (hu) 2019-11-28
EP3292133A1 (de) 2018-03-14
TW201713651A (zh) 2017-04-16
EP3292133B1 (de) 2019-06-26
PL3292133T3 (pl) 2019-12-31
PH12017502010A1 (en) 2018-03-26
CU20170136A7 (es) 2018-02-08
PT3292133T (pt) 2019-09-18
UY36664A (es) 2016-11-30
MX2017014134A (es) 2018-03-15
MA42039A (fr) 2018-03-14
PE20180204A1 (es) 2018-01-31
DK3292133T3 (da) 2019-09-23
WO2016188711A1 (de) 2016-12-01
CN107531688A (zh) 2018-01-02
US20180155336A1 (en) 2018-06-07
ES2744227T3 (es) 2020-02-24
KR20180002698A (ko) 2018-01-08
CL2017002764A1 (es) 2018-05-25
AU2016268920A1 (en) 2017-11-09
IL255208A0 (en) 2017-12-31
TN2017000466A1 (en) 2019-04-12
BR112017023852A2 (pt) 2018-07-17
JP2018516882A (ja) 2018-06-28
CA2984984A1 (en) 2016-12-01
ECSP17072780A (es) 2017-12-01
LT3292133T (lt) 2019-08-26
HRP20191596T1 (hr) 2019-11-29
EA201792422A1 (ru) 2018-02-28

Similar Documents

Publication Publication Date Title
EP3291814A4 (en) Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl) cyclopropanamine, its crystalline form and its salts
BR112015022191A8 (pt) compostos heteroarila e usos dos mesmos
DK2800746T3 (da) Fremgangsmåde til fremstilling af 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazin
WO2014132270A3 (en) Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
BR112013030163A2 (pt) composto, uso cosmético de pelo menos um composto, composição farmacêutica ou cosmética e processo para preparar um composto.
IL239940B (en) History of 2-[3-(diazolyl)phenyl]-3,1-thiazole-5-carboxylic acid and intermediates obtained in the process for their preparation
CO2017011294A2 (es) Procedimiento para la preparación de 2-{4-[2-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-3,5-diciano-6-(pirrolidin-1-il)piridina-4-il]fenoxi}etil-l-alanil-l-alaninato-monohidrocloruro
SG11201709593VA (en) CRYSTAL OF (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]- 4,7-DIOXO-8-({6-[3-(PIPERAZIN-1-YL)AZETIDIN-1-YL]PYRIDIN- 2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND
MX2015014688A (es) Tiazoles y usos de los mismos.
BR112017009471A2 (pt) síntese de copanlisib e seu sal de di-hidrocloreto.
EP3372590A4 (en) Compounds having agonistic effect for gpr84, preparation method for compounds and use of compounds
MX2016009667A (es) Forma cristalina alfa del compuesto a monobenzoato y método de preparación de la misma y composición farmacéutica que comprende la misma.
EP3212640A4 (en) Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
WO2015018507A3 (en) A novel process for the preparation of febuxostat
BR112014028632A2 (pt) composto , composição farmacêutica , e , métodos de prepara um composto e de tratamento de uma infecção viral
BR112018012095A2 (pt) formas sólidas de compostos substituidos de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina
GB2559718B (en) Novel crystalline form of tribenuron-methyl, process for preparation and use thereof
SG11201701674RA (en) Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
AR098134A1 (es) Compuestos de urea
WO2014167509A3 (en) Loxoprofen polymorphs and process for preparation of the same
BR112016024521A2 (pt) sais e polimorfos de um composto imidazopiridinil-aminopiridina
BR112017018248A2 (pt) composto metalorgânico
WO2014125233A3 (fr) Procédé de synthèse de 4-piperidin-4-yl-benzène-1,3-diol et de ses sels et nouveau composé 4-(2,4-dihydroxy-phényl)-4-hydroxy-piperidine-1-carboxylate de tert-butyle
IN2013MU00777A (es)
BR112018011589A2 (pt) método para preparar um composto, e, composto.